<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article296</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/WARSS" style="display:block; margin-bottom:10px;">WARSS Original</a></li>
<h2><strong>WARSS</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Warfarin vs. Aspirin in Patients with Recurrent Ischemic Stroke".The New England Journal of Medicine. 2001. 345(20):1444-1451.PubMed•Full text•PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcome<br/>
8.2 Secondary Outcomes<br/>
9 Criticisms<br/>
10 Funding<br/>
11 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In patients with prior noncardioembolic ischemic stroke, is warfarin superior to aspirin in preventing recurrent ischemic stroke or death?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In patients with prior noncardioembolic ischemic stroke, warfarin was not superior to aspirin in preventing recurrent ischemic stroke or death and both were considered reasonable therapeutic alternatives.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
As of 2001, guidelines have not been updated to reflect the results of this trial.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, double-blind, randomized trial<br/>
- N=2,206 patients with recent ischemic stroke<br/>
- Warfarin (target INR 1.4 to 2.8)<br/>
- Aspirin (325 mg per day)<br/>
- Enrollment: 1993-2000<br/>
- Mean follow-up: 2 years<br/>
- Analysis: Intention-to-treat<br/>
- Primary outcome: Composite of recurrent ischemic stroke or death from any cause within two years<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria<br/>
- Age 30-85 years<br/>
- Acceptable candidates for warfarin therapy<br/>
- Had an ischemic stroke within the previous 30 days<br/>
- Glasgow Outcome Scale score of 3 or higher<br/>
<br/>
Exclusion Criteria<br/>
- Baseline INR &gt;1.4<br/>
- Stroke due to high-grade carotid stenosis planned for surgery<br/>
- Stroke associated with inferred cardioembolic source, e.g., atrial fibrillation<br/>
<br/>
Baseline Characteristics<br/>
- Similar between both treatment groups<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Warfarin dose adjusted to maintain an INR 1.4 to 2.8<br/>
- Aspirin 325 mg daily<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcome<br/>
- No significant difference in the rate of recurrent ischemic stroke or death between warfarin and aspirin (17.8% with warfarin vs. 16.0% with aspirin, P=0.25)<br/>
<br/>
Secondary Outcomes<br/>
- Rates of major hemorrhage were low and not significantly different between treatment groups<br/>
- Minor hemorrhages were more frequent in the warfarin group<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- The study did not have sufficient power to show differences in treatment effects among various clinically identified stroke subtypes.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Supported by a grant from the National Institute of Neurological Disorders and Stroke. Medications and placebos were supplied by Dupont Pharmaceuticals and Bayer.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
The original publication and accompanying editorial in "The New England Journal of Medicine" are suggested for further reading.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
